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CRPAbstract Objectives: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
describes the phenomenon of sudden worsening in airway function and respiratory symptoms in
patients with COPD. The aim of this work is to study the value of copeptin and C-reactive protein
in AECOPD.
Patients and methods: The study enrolled 31 patients with AECOPD and 10 control subjects. All
patients were subjected to history taking, clinical examination, arterial blood gases analysis and
sputum culture for bacteriological examination. Serum samples were obtained from the patients
on admission, 3 days and 14 days after and from control subjects. The samples were analyzed for
copeptin and CRP levels.
Results: The copeptin level on admission was signiﬁcantly higher in AECOPD patients than the
control subjects. The copeptin and CRP showed a statistically signiﬁcant decline over the study
duration but did not correlate with each other. ROC analysis curve showed that a copeptin level
>14 pg/dl on admission had a sensitivity of 70% and speciﬁcity of 90% in predicting AECOPD
and a level of >15 pg/dl on the fourteenth day had a sensitivity of 100% and speciﬁcity of 90%
in predicting in-hospital mortality. Copeptin correlated signiﬁcantly directly with the presence of
bacterial infection and inversely with both PaO2 and PaCO2. Neither the copeptin nor CRP corre-
lated with the COPD severity as expressed by the FEV1%, BODE index and previous history of
exacerbations.
Conclusion: Copeptin has a good sensitivity and excellent speciﬁcity in predicting AECOPD.
Additionally, it has good predilection for short term outcome and in-hospital mortality.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
common health problems worldwide and in Egypt [1,2]. It is
854 T.S. Morsi, A. A.-E. Degadywell accepted in the time being that COPD is not simply a local
pulmonary disease but associated with systemic inﬂammatory
process [3]. Acute exacerbation of COPD (AECOPD)
describes the phenomenon of sudden worsening in airway
function and respiratory symptoms in patients with COPD
and contributes to the overall severity of the disease in individ-
ual patients [4]. Clinical judgment of the severity of the acute
exacerbation is still the main reliable verdict. Various airway
and systemic inﬂammatory markers are studied in both the sta-
ble and exacerbated phases of the disease [5,6]; and there is
abundant evidence that both pan-airway and systemic inﬂam-
mation are augmented in association with AECOPD [7]. C-
reactive protein (CRP) is an acute-phase protein which rises
in response to inﬂammation. Recently, there is an evidence
that CRP is not just a marker of COPD but also contributes
to pathogenesis and increases during AECOPD [8].
Copeptin, a 39-amino-acid-long peptide, is the C-terminal
part of pro-arginine vasopressin and is released together with
vasopressin during processing of the precursor peptide. Vaso-
pressin, the antidiuretic hormone produced by the hypothala-
mus, is the key hormone involved in the hemodynamic and
osmotic control and mirrors the individual stress level; but
its instability precludes its routine use and makes reliable mea-
surements difﬁcult to achieve [9]. In contrast to vasopressin,
copeptin is stable at room temperature in serum and plasma
and can be measured as a ‘shadow’ fragment of vasopressin
in the circulation [10]. the last years, copeptin was studied in
a variety of clinical conditions, such as AECOPD, hemor-
rhagic and septic shock, myocardial infarction, heart failure
and cerebrovascular stroke [11–14].
Objectives
The aim of this work is to study the value of copeptin and C-
reactive protein in acute exacerbation of chronic obstructive
pulmonary disease.Patients and methods
Study design and population
A case control study enrolled 31 patients with acute exacerba-
tion of COPD-attending the Chest Diseases Department of
Alexandria Main University Hospital, Alexandria, Egypt-
and 10 non-COPD participants with matched age and sex as
a control group. All of the patients had a previous diagnosis
of COPD according to the GOLD guideline [4] with a clinical
evidence of exacerbation according to the previously accepted
symptom-based deﬁnition [15]. Patients with evidence of con-
founding inﬂammatory diseases (such as malignancy, arthritis,
connective tissue disorders or inﬂammatory bowel disease) or
other pulmonary diseases (as asthma, tuberculosis or bronchi-
ectasis) were excluded from the study. The study was approved
by the local ethics committee and all participants signed an
informed consent.
On admission, all of the patients were subjected to history
taking, clinical examination, arterial blood gas analysis, plain
chest X-ray, sputum culture for bacteriological examination
and blood sample taking. After the initial evaluation of thestudied group, the patients were managed according to the
international guidelines. They were assigned to the standard
drug protocol and supplemental oxygen therapy plus non-inva-
sive ventilation (NIV). The standard drug protocol consisted of
nebulized salbutamol (2 mg every 4 h), nebulized ipratropium
bromide (500 lg every 6 h), corticosteroids (prednisolone
30 mg every day for a minimum of 5 days), aminophylline
and an empirical antibiotic changeable after the antibiotic sen-
sitivity testing if indicated. The administered fraction of
inspired oxygen was adjusted to maintain arterial oxygen satu-
ration values of 88–92%. Endotracheal intubation and invasive
mechanical ventilation were introduced in case of failure of
NIV trial. All of the patients were followed up for 14 days.
Inﬂammatory markers
Three serum samples were obtained from the patients: on
admission, 3 days and 14 days after. A serum sample was also
taken from the control subjects. All the samples were preserved
in 80 C till the end of the study period. The collected sam-
ples were analyzed for copeptin and CRP. The copeptin was
measured by ELISA kit (Wuhan ElAab Science Co. Ltd,
China) following the manufacturers’ instructions. This immu-
noassay test allows for the in vitro quantitative determination
of human copeptin concentrations in serum and plasma.
The ELISA is based on the competitive binding enzyme
immunoassay technique. The microtiter plate provided has
been pre-coated with an antibody speciﬁc to copeptin. During
the reaction, copeptin in the sample or standard competes with
a ﬁxed amount of biotin-labeled copeptin for sites on a pre-
coated Monoclonal antibody speciﬁc to copeptin. Excess con-
jugate and unbound sample or standard are washed from the
plate. Next, Avidin conjugated to Horseradish Peroxidase
(HRP) is added to each microplate well and incubated. Then
a TMB substrate solution is added to each well. The
enzyme–substrate reaction is terminated by the addition of a
sulfuric acid solution and the color change is measured spec-
trophotometrically at a wavelength of 450 nm ± 2 nm. The
concentration of copeptin in the samples is then determined
by comparing the O.D. of the samples to the standard curve.
No signiﬁcant cross-reactivity or interference was observed.
Ultrasensitive-CRP was measured in serum samples by
CRP-ultrasensitive (MICRO CRP/ ULTRA CRP, Vital Diag-
nostics, Italy). CRP was measured using the quantitative turbi-
dimetric latex technique by Turbi-Quick machine (Vital
Diagnostics S.r.l. via Balzella 41/g/4, 47100 Forlı`, Italy). Latex
particles coated with speciﬁc anti-human CRP were aggluti-
nated when mixed with serum samples containing CRP. The
agglutination caused an absorbance change, dependent upon
the CRP contents of the serum sample that can be quantiﬁed
by comparison from a caliber of known CRP concentration.
According to the manufacturers’ directions, the latex was sha-
ken gently and diluted in the following way (1 ml latex
reagent + 14 ml diluent (1:15)). Also, the samples and controls
were diluted in this way (50 ll sample or control + 450 ll NaCl
9 g/L (1:10)). From each prepared reagent, 500 ll was incu-
bated in positions 1–4 in special cuvettes for at least 1 min,
and then transferred in the reading channel. When requested
in the display, 50 ll of the diluted sample was added. The
results appeared automatically on the reader display after 240 s.
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All the data were presented as mean ± standard deviation
(SD) or number and percentage (%) as appropriate. Compar-
isons between groups were performed using Mann–Whitney
(for two independent groups) or Kruskal–Wallis tests (for
three independent groups). The Spearman correlation coefﬁ-
cient (rho) test was used for the correlation between different
parameters. The prognostic performance of CRP and copeptin
predicts both the onset of exacerbation and the resolution of
the event which were evaluated using Receiver Operating
Characteristic (ROC) curve analysis. In a ROC curve the ‘‘sen-
sitivity’’ is plotted against ‘‘100-speciﬁcity’’ for different cut-off
points of each of CRP and copeptin. The area under the ROC
curve (AUC) is a measure of how well each of CRP and copep-
tin can distinguish between two prognostic groups. The sensi-
tivity, speciﬁcity, positive and negative predictive value of each
marker were calculated accordingly. MedCalc (version
9.2.1.0, Acacialaan 22, B-8400 Ostend, Belgium) was used
for data analysis. All of the statistical tests used in the analysis
were two sided where p< 0.05 was considered as signiﬁcant.
The 95% conﬁdence interval (CI) has been shown.
Results
Study population
Table 1 shows the baseline characteristic data of the involved
patients. The mean age of the patients was 56.6 ± 7.9 years,Table 1 The characteristics of the patients.
Character COPD Cases (n = 31)
Age; mean ± SD 56.6 ± 7.9
Gender (M/F); n (%) 24 (77.4%)/7 (22.6%)
Current smoker; n (%) 11 (35.5)
Smoking index; mean ± SD 40.9 ± 22.5
Dyspnea (MMRC); mean ± SD 2.7 ± 0.97
BMI (Kg/m2); mean ± SD 28.01 ± 8.4
BODE index; mean ± SD 5.3 ± 2.4
History of repeated exacerbation
(P3/year); n (%)
22 (71%)
Pulmonary function test
FEV1/FVC; mean ± SD 54.5 ± 11.9
FEV1 (L); mean ± SD 1.22 ± 0.59
FEV1%; mean ± SD 44.3 ± 19.6
FVC (L); mean ± SD 2.24 ± 0.97
FVC%; mean ± SD 60.3 ± 22.7
Arterial blood gases
pH; mean ± SD 7.31 ± 0.06
PaO2 (mmHg); mean ± SD 47.65 ± 13.3
PaCO2 (mmHg); mean ± SD 69.5 ± 16.8
HCO3 (mmol/L); mean ± SD 34 ± 7
SaO2 (%); mean ± SD 74.5 ± 11.8
COPD, chronic obstructive lung disease; M, male; F, female;
MMRC, modiﬁed medical research council dyspnea scale; BMI,
Body mass index; Kg/m2, kilogram/square meter; FVC, forced vital
capacity; FEV1, forced expiratory volume in the ﬁrst second; L, liter;
pH, hydrogen ion concentration; PaCO2, arterial partial pressure of
carbon dioxide; PaO2, arterial partial pressure of oxygen; SaO2,
oxygen saturation in arterial blood; HCO3, bicarbonate level.while that of the control group was 55.8 ± 4.6 years; with no
statistical difference between the two groups. Twenty four
(77.4%) patients were males and seven (22.6%) were females.
The smoking index was 40.9 ± 22.5 where 35.5% of the
COPD cases who presented with exacerbation were current
smokers and 71% of the patients had a history of repeated
exacerbation in the last year (P3/year). The enrolled patients
were moderate to very severe COPD as showed in the spiro-
metric test with an average BODE index of 5.3 ± 2.4 (Table 1).
Bacteriological organism as a cause of exacerbation was iden-
tiﬁed in 61.2% of the recruited sputum samples.
Serum inﬂammatory markers
The copeptin level on admission among the patients with
AECOPD was signiﬁcantly higher compared to the control
group (20.7 ± 11.2 pg/dl vs. 11.4 ± 2.41 pg/dl respectively,
p= 0.0017; Fig. 1A). The copeptin level showed a statistical
signiﬁcant difference over the study duration (p= 0.011;
Fig. 1B); where it was higher on admission compared to the
3rd and 14th days (20.7 ± 11.2 pg/dl, 15.8 ± 5.4 pg/dl and
13.1 ± 2.7 pg/dl respectively). Additionally, the copeptin was
statistically signiﬁcantly lower on the 14th day compared to
the admission day (p= 0.005); (Table 2). Similarly, the CRP
showed a statistically signiﬁcant change over the study dura-
tion (p= 0.013; Table 2); however, neither a signiﬁcant
decrease of its level after 14 days of AECOPD nor a signiﬁcant
correlation with the copeptin level have been encountered
(r= 0.085, p= 0.466).
Using the Receiver Operating Characteristic (ROC) analy-
sis curve, a copeptin level >14 pg/dl on admission had a sen-
sitivity of 70% and speciﬁcity of 90% in predicting AECOPD
(AUC= 0.842, 95% CI= 0.682 to 0.941, p= 0.0001;
Fig. 2A) with 95% and 54% of positive and negative predictive
values, respectively.
Correlations
On the third day after admission, the copeptin level had a sta-
tistically direct signiﬁcant correlation with the presence of
bacterial infection on admission (r= 0.455, p= 0.033;
Fig. 3A) and an inverse correlation with PaO2 (r= 0.403,
p= 0.044; Fig. 3B). On the fourteenth day, the copeptin
correlated signiﬁcantly and inversely with PaCO2 level on
admission (r= 0.520, p= 0.0147; Fig. 3C). Neither the
copeptin nor CRP correlated with the COPD severity as
expressed by the FEV1%, BODE index and previous history
of exacerbations (p> 0.05).
Outcome
Among the AECOPD patients, 77.4% (24 patients) completed
the study duration while 22.6% died (7 patients). The copeptin
level was signiﬁcantly higher among those who died compared
to the survivors after 14 days (12.6 ± 2.3 vs. 18 ± 2.8 pg/dl,
p= 0.029; Fig. 4); but not on admission nor after 3 days
(p> 0.05; Fig. 4A). Using the ROC analysis, the copeptin
level >15 pg/dl on the fourteenth day had a sensitivity of
100% and speciﬁcity of 90% in predicting in-hospital mortal-
ity (AUC= 0.976, 95% CI= 0.810 to 0.987, p= 0.0001;
Fig. 2B) with 48.8% and 100% of positive and negative
Figure 1 (A) Copeptin level comparison between AECOPD
patients on admission and the control subjects; (B) Comparison
between the levels of copeptin among the AECOPD patients over
the study duration (admission day, after 3 days and after 14 days).
856 T.S. Morsi, A. A.-E. Degadypredictive values respectively. On the other hand, CRP had no
similar signiﬁcant difference between the survivors and the
deceased patients despite being higher among the latter
(Fig. 4B). However, on the fourteenth day, CRP level
>2.5 mg/L had a sensitivity of 100% in predicting in-hospital
mortality with a low speciﬁcity of 60% (AUC= 0.659, 95%
CI= 0.439 to 0.838, p= 0.472).Table 2 The biomarkers over the study duration.
Biomarker Time
On admission On 3rd day
Copeptin 20.7 ± 11.2 15.8 ± 5.4
z= 1.4, p= 0.162 (1);
z= 1.913, p= 0.056 (2);
z= 2.785, p = 0.005 (3)
CRP 2.7 ± 1.04 1.7 ± 1.2
z= 3.093, p = 0.002 (1);
z= 1.07, p= 0.284 (2);
z= 1.304, p= 0.192 (3)
(1) Difference between admission and 3rd day values; (2) Difference betw
14th day’s values.Discussion
AECOPD is considered as the most common complication of
COPD and is associated with accelerated decline in FEV1 [16],
poorer quality of life [17] and increased mortality [18].
However, the diagnosis of AECOPD is symptom-based [15].
Accordingly, various biomarkers have been evaluated in
AECOPD in order to add an additional tool for the diagnosis
of these events, predict their severity or mortality. In our
study, we evaluated both copeptin and CRP as biomarkers
of exacerbations and we assessed their value in the diagnosis
of AECOPD and its outcome.
Stolz et al. [11] found in their study that copeptin was supe-
rior to CRP and procalcitonin in predicting the in-hospital
outcome and length of hospital stay in patients with AECOPD
as well as being signiﬁcantly higher on hospital admission.
Sharples et al. [19] found in their work that copeptin is signif-
icantly increased in bacterial infection. Another study reported
higher copeptin level with increasing severity of lower respira-
tory tract infection and unfavorable outcome especially among
patients with acute bronchitis and AECOPD [20]. Our results
agreed with these studies; as we found that copeptin level on
admission was signiﬁcantly higher compared to control sub-
jects and signiﬁcantly changed over the course of the exacerba-
tion. In addition, the copeptin after 14 days of exacerbation
was signiﬁcantly higher in patients who died during hospital
stay. The copeptin level >15 pg/dl presented a sensitivity of
100% and speciﬁcity of 90% in predicting in-hospital mortal-
ity, rendering this biomarker extremely effective in predicting
short term outcome of AECOPD.
In our study, in spite of its high sensitivity (up to 100%),
CRP did not show signiﬁcant relation to in-hospital mortal-
ity; a ﬁnding in agreement with that of Stolz et al [11]. This
could be explained by the high sensitivity of the CRP which
rises during infection or acute injury to just decline after van-
ishing of the initial stimulus rendering it a sensitive non-spe-
ciﬁc maker [21]. However, CRP showed a signiﬁcant change
over the duration of the study. This is attributed to the sig-
niﬁcant decrease after 3 days of therapy among the patients
which could be secondary to corticosteroids used in the man-
agement of AECOPD [22], non-invasive ventilation [23] and
the use of antibiotics which could modulate the systemic
inﬂammatory response secondary to infection eradication.p Value
On 14th day
13.1 ± 2.7 z= 8.963 p= 0.011*
2.13 ± 1.5 z= 8.624 p= 0.013*
een 3rd and 14th day’s values; (3) Difference between admission and
Figure 2 ROC for the copeptin. A: for predicting exacerbation
(AUC= 0.976, 95% CI= 0.810 to 0.987, p= 0.0001), B: for
predicting mortality (AUC= 0.842, 95% CI= 0.682 to 0.941,
p= 0.0001). Figure 3 Correlations. (A) Copeptin after 3 days and the
presence of bacterial infection; (B) Copeptin after 3 days and
PaO2 after 3 days; (C) Copeptin after 14 days and PaCO2 on
admission.
Copeptin and C-reactive protein in acute exacerbation of COPD 857On the other hand, CRP increased after 14 days of exacerba-
tion but did not reach a statistical signiﬁcance. Indeed, Perera
et al. [24] found an insigniﬁcant improvement of the CRP on
the 14th day and on the 35th day of exacerbation which
denoted persistent systemic inﬂammation post-exacerbation.
They also speculated that a raised CRP concentration 14 days
after exacerbation onset may be predictive of recurrence
within the subsequent 50 days. Seemungal et al. [25] sug-
gested that the inﬂammation can take months after the exac-
erbation episode to resolve.
Bacterial infection, as a cause of AECOPD, was identiﬁed
in 61.2% of the cases falling within the percentages in previous
publications [26]. Interestingly, the copeptin level after 3 days
of acute event correlated directly with the presence of bacterial
infection on admission. This could explain the persistence of
higher copeptin level in those patients [20] and the non-signif-
icant change among the studied cohort (table 2) compared to a
signiﬁcant change after 14 days of therapy. Additionally, the
copeptin correlated inversely with PaO2 measured 3 days after
the exacerbation. This ﬁnding was reported in previouspublications which may be explained on the basis that vaso-
pressin causes vasoconstriction which correlates to the hypoxia
induced-vasoconstriction in severe COPD [27–29]. However
we did not ﬁnd any correlation between the copeptin level
and the underlying severity of the COPD or the previous his-
tory of exacerbations. This was partially agreed by Stolz
et al. [11] as they did not ﬁnd correlation between the copeptin
and FEV1% but there was a trend for a positive correlation
with a previous history of hospitalization secondary to
AECOPD. This difference could be due to variability in the
characteristics of the recruited patients as the majority of our
patients were severe to very severe COPD and 71% have a
repeated history of exacerbation in the last year. Nevertheless,
Seligman et al. [30] found that copeptin increased in patients
with critical care illness and correlated with the severity of
the primary disease.
Figure 4 Comparison between the survived and dead patients over the study duration regarding copeptin levels (A) and CRP levels (B).
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Copeptin is an acceptable biomarker aiding in the diagnosis of
the AECOPD with a good sensitivity and excellent speciﬁcity
in predicting AECOPD irrespective of the underlying severity
of the disease. Additionally, copeptin could be used for follow-
ing up the resolution of the exacerbation and short term out-
come as it showed a good predilection of in-hospital
mortality over CRP.Conﬂict of interest
We have no conﬂict of interest to declare.
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